- Gout is referred to as a general form of inflammatory arthritis. Gout is caused because of higher levels of uric acid in the blood. Main risk factors that are likely to cause gout are certain health factors such as high blood pressure, high cholesterol and specific medications that can cause high levels of uric acid. Also, the factors like diet containing red meat, obesity, and high consumption of alcohol can cause gout.
- The demand for gout treatment is significantly driven by the rising prevalence of gout, increasing awareness through public health campaigns, and advancements in diagnostic technologies such as uric acid level testing and imaging tools.
- North America is expected to dominate the gout treatment market with a share of 36.4%, attributed to advanced healthcare infrastructure, high adoption of innovative gout treatment therapies, and the presence of leading biopharmaceutical companies specializing in gout treatments.
- Asia-Pacific is projected to be the fastest-growing region in the gout treatment market during the forecast period due to improving healthcare access, growing awareness of gout, and the increasing availability of specialized treatments.
- The Tophaceous Gout segment is expected to lead the market with a share of 34.5% due to its higher prevalence in patients with long-term, untreated gout, early diagnosis rates, and established treatment protocols. The widespread use of urate-lowering therapies (ULTs) such as allopurinol and febuxostat, along with clinician familiarity, supports its dominant position in the market.
